FDA Approves TECENTRIQ® and ABRAXANE® Combination for Advanced Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC) is a heterogeneous, molecularly diverse group of breast cancers and are ER (Estrogen Receptor), PR (Progesterone Receptor) and HER2 (Human Epidermal Growth Factor Receptor-2) negative. Those with metastatic disease have one of the worst prognosis of all cancers with a median Overall Survival of 13 months.

TECENTRIQ® (Atezolizumab) an anti PD-L1 monoclonal antibody given along with ABRAXANE® (Nanoparticle Albumin-Bound – nab Paclitaxel) improved the Progression Free Survival (PFS) by 20%, when compared with ABRAXANE® alone. This benefit was even more significant among patients with PD-L1–positive tumors with PFS improvement of 38%. The combination of TECENTRIQ® plus ABRAXANE® could potentially change how we manage patients with Triple Negative Breast Cancer.